πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 650 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11873291

Quinoline cGAS antagonist compounds

The Board of Regents of the University of Texas System Β· Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866503

Methods for treating inflammatory conditions of the airway or lungs by administering antag

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11858943

Vasopressin receptor antagonists and products and methods related thereto

Neumora Therapeutics, Inc. Β· Granted Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11845800

Methods for treating or preventing asthma by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11844765

Treatment of inflammatory conditions by delivery of interleukin-1 receptor antagonist fusi

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Dec 19 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 14 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11840581

Ξ±4Ξ²7 thioether peptide dimer antagonists

Protagonist Therapeutics, Inc. Β· Granted Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11834409

Heterocyclic NMDA antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11827601

Heterocyclic NMDA antagonists

Takeda Pharmaceutical Company Limited Β· Granted Tue Nov 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11806398

Citrate buffered VEGF antagonist formulations

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Nov 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11771743

Methods for preventing or treating allergy by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11744800

Methods of use of emulsion formulations of an NK-1 receptor antagonist

Heron Therapeutics, Inc. Β· Granted Tue Sep 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 31 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11730705

Small molecule CMKLR1 antagonists in inflammatory disease

United States Government as represented by the Department of Veterans Affairs Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11730794

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11732024

VEGF antagonist formulations suitable for intravitreal administration

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11718679

CD137 antibodies and PD-1 antagonists and uses thereof

Compass Therapeutics LLC Β· Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11713324

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11707506

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Jul 25 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 20 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11690825

20-HETE receptor (GPR75) antagonists and methods of use

The Board of Regents of the University of Texas System Β· Granted Tue Jul 04 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 29 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11666547

Methods for treating cognitive deficits in a subject having schizophrenia, bipolar disorde

Northwestern University Β· Granted Tue Jun 06 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11603408

Methods for treating skin infection by administering an IL-4R antagonist

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Mar 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11597707

CGAS antagonist compounds

The Board of Regents of the University of Texas System Β· Granted Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11590135

Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagoni

Corcept Therapeutics Incorporated Β· Granted Tue Feb 28 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11584736

Heterocyclic P2Y14 receptor antagonists

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Feb 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11571412

Thromboxane receptor antagonists in AERD/asthma

Cumberland Pharmaceuticals Inc. Β· Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted